Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stem Cells Therapy in Degenerative Diseases of the Retina
NCT03772938Phase 1Unknown
- Sponsor
- Pomeranian Medical University in Szczecin
- Start
- Dec 2018
- Primary completion
- Feb 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous bone marrow-derived mononuclear cell in retinal degeneration, retinitis pigmentosa (RP), age-related macular degeneration (AMD) and 1 more (2 arms), sponsored by Pomeranian Medical University in Szczecin. Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at 12 months. Status: unknown.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
retinal degenerationretinitis pigmentosa (RP)age-related macular degeneration (AMD)Stargardt disease (STGD)
Beyond the preview
Go deeper on NCT03772938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03772938.